# Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria

> **NCT00529867** · PHASE4 · COMPLETED · sponsor: **Dafra Pharma** · enrollment: 267 (actual)

## Conditions studied

- Malaria, Falciparum

## Interventions

- **DRUG:** Artemether/lumefantrine tablets
- **DRUG:** Artemether/Lumefantrine suspension

## Key facts

- **NCT ID:** NCT00529867
- **Lead sponsor:** Dafra Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2008-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529867, "Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00529867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*